Last reviewed · How we verify
Soticlestat 300 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Soticlestat 300 mg (Soticlestat 300 mg) — Takeda.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Soticlestat 300 mg TARGET | Soticlestat 300 mg | Takeda | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Soticlestat 300 mg CI watch — RSS
- Soticlestat 300 mg CI watch — Atom
- Soticlestat 300 mg CI watch — JSON
- Soticlestat 300 mg alone — RSS
Cite this brief
Drug Landscape (2026). Soticlestat 300 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/soticlestat-300-mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing